Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450281 · ClinicalTrials.gov registry record
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
A clinical trial of Lung Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 981
- Enrollment target
- 20
- Study locations
NCT00450281 is a study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 981 participants, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 4 states.
The verdict
NCT00450281, a study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 981 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC mutation analysis
- GENETIC polymerase chain reaction
- GENETIC polymorphism analysis
- GENETIC chromogenic in situ hybridization
Study Locations (20)
California
- Kaiser Permanente - Deer Valley - Antioch
- Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center - Burbank
- Cancer Care Center at John Muir Health - Concord Campus - Concord
- North Bay Cancer Center - Fairfield
- Kaiser Permanente - Fremont - Fremont
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- Kaiser Permanente Medical Center - Hayward - Hayward
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
- Kaiser Permanente Medical Center - Oakland - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
- Valley Care Medical Center - Pleasanton
- Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center - Pomona
- Kaiser Permanente Medical Center - Redwood City - Redwood City
- Kaiser Permanente Medical Center - Richmond - Richmond
- Kaiser Permanente Medical Center - Roseville - Roseville
- University of California Davis Cancer Center - Sacramento
- Mercy General Hospital - Sacramento
Alaska
- Providence Cancer Center - Anchorage
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 981 participants |
| Start Date | 2005-10 |
| Est. Completion | 2012-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450281
The ClinicalTrials.gov registry entry for NCT00450281 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 981 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00450281 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT00450281 about?
NCT00450281 is a clinical study titled "S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for...
What is the current status of trial NCT00450281?
This trial is currently completed. The enrollment target is 981 participants. The study started on 2005-10. Estimated completion is 2012-07.
What conditions does trial NCT00450281 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00450281?
The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), polymerase chain reaction (GENETIC), polymorphism analysis (GENETIC), chromogenic in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00450281?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00450281 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.